GFR Decline As An Alternative End Point in Clinical Trials to Prevent ESRD: Are we increasing treatment uncertainty for the sake of feasibility?

American Journal of Kidney Diseases

Volumn 64, Issue 6, 2014, Pages 841-844

  Sontrop, Jessica M ^a,b   Al Jaishi, Ahmed A ^b   Garg, Amit X ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CREATININE; IRBESARTAN; LOSARTAN;

BLOOD PRESSURE REGULATION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; END STAGE RENAL DISEASE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; META ANALYSIS (TOPIC); PROTEIN RESTRICTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE; BIOASSAY; KIDNEY FAILURE, CHRONIC; PHYSIOLOGY; PROCEDURES;

ENDPOINT DETERMINATION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84910648473     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.10.002     Document Type: Editorial

References (24)

1. M. Jun, C.T. Turin, H. Lambers Heerspink, V. Perkovic, and B. Hemmelgarn The validity of doubling of serum creatinine as a surrogate marker for ESRD: a systematic review of randomized controlled trials J Am Soc Nephrol 24 2013 150A
2. A.S. Levey, L.A. Inker, and K. Matsushita GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration Am J Kidney Dis 64 6 2014 821 835
3. H.J. Lambers Heerspink, H. Tighiouart, and Y. Sang GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials Am J Kidney Dis 64 6 2014 860 866
4. L.A. Inker, H.J. Lambers Heerspink, and H. Mondal GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials Am J Kidney Dis 64 4 2014 848 859
5. A.S. Levey, D. Cattran, and A. Friedman Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration Am J Kidney Dis 54 2 2009 205 226
6. L.A. Stevens, T. Greene, and A.S. Levey Surrogate end points for clinical trials of kidney disease progression Clin J Am Soc Nephrol 1 4 2006 874 884
7. K. Matsushita, E. Selvin, L.D. Bash, N. Franceschini, B.C. Astor, and J. Coresh Change in estimated GFR associates with coronary heart disease and mortality J Am Soc Nephrol 20 12 2009 2617 2624
8. M.G. Shlipak, R. Katz, and B. Kestenbaum Rapid decline of kidney function increases cardiovascular risk in the elderly J Am Soc Nephrol 20 12 2009 2625 2630
9. T.C. Turin, J. Coresh, and M. Tonelli Short-term change in kidney function and risk of end-stage renal disease Nephrol Dial Transplant 27 10 2012 3835 3843
10. T.C. Turin, J. Coresh, and M. Tonelli One-year change in kidney function is associated with an increased mortality risk Am J Nephrol 36 1 2012 41 49
11. T.C. Turin, J. Coresh, and M. Tonelli Change in the estimated glomerular filtration rate over time and risk of all-cause mortality Kidney Int 83 4 2013 684 691
12. D.E. Rifkin, M.G. Shlipak, and R. Katz Rapid kidney function decline and mortality risk in older adults Arch Intern Med 168 20 2008 2212 2218
13. R.M. Perkins, I.D. Bucaloiu, H.L. Kirchner, N. Ashouian, J.E. Hartle, and T. Yahya GFR decline and mortality risk among patients with chronic kidney disease Clin J Am Soc Nephrol 6 8 2011 1879 1886
14. Z. Al-Aly, A. Zeringue, and J. Fu Rate of kidney function decline associates with mortality J Am Soc Nephrol 21 11 2010 1961 1969
15. Z. Al-Aly, S. Balasubramanian, J.R. McDonald, J.F. Scherrer, and A.M. O'Hare Greater variability in kidney function is associated with an increased risk of death Kidney Int 82 11 2012 1208 1214
16. J. Skupien, J.H. Warram, and A.M. Smiles The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease Kidney Int 82 5 2012 589 597
17. J. Coresh, T.C. Turin, and K. Matsushita Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality JAMA 311 24 2014 2518 2531
18. A. Chang, and H. Kramer CKD progression: a risky business Nephrol Dial Transplant 27 7 2012 2607 2609
19. L. Li, B.C. Astor, J. Lewis, and B. Hu Longitudinal progression trajectory of GFR among patients with CKD Am J Kidney Dis 59 4 2012 504 512
20. T.C. Turin, and B.R. Hemmelgarn Improvement in kidney function: a real occurrence J Am Soc Nephrol 23 4 2012 575 577
21. H.J. Lambers Heerspink, M. Weldegiorgis, and L.A. Inker Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial Am J Kidney Dis 63 2 2014 244 250
22. A.S. Levey, T. Greene, and M.J. Sarnak Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study Am J Kidney Dis 48 6 2006 879 888
23. M.S. Lauer, and R.B. D'Agostino The randomized registry trial - the next disruptive technology in clinical research? N Engl J Med 369 17 2013 1579 1581
24. N. Kozauer, and R. Katz Regulatory innovation and drug development for early-stage Alzheimer's disease N Engl J Med 368 13 2013 1169 1171